Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (... Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patients treatment location, making them what we believe to be off-the-shelf. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. 더 보기
Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune...
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...
Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK®...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.28 | -2.44969378828 | 11.43 | 12.17 | 10 | 56895 | 10.55299472 | CS |
4 | 0.13 | 1.17967332123 | 11.02 | 15.49 | 9.68 | 56298 | 11.62380601 | CS |
12 | 0.05 | 0.45045045045 | 11.1 | 17.31 | 9.68 | 142880 | 12.49801785 | CS |
26 | -4.85 | -30.3125 | 16 | 17.31 | 9.68 | 139570 | 12.1692114 | CS |
52 | -4.85 | -30.3125 | 16 | 17.31 | 9.68 | 139570 | 12.1692114 | CS |
156 | -4.85 | -30.3125 | 16 | 17.31 | 9.68 | 139570 | 12.1692114 | CS |
260 | -4.85 | -30.3125 | 16 | 17.31 | 9.68 | 139570 | 12.1692114 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관